Comparison of novel missense mutations in Spanish HA patients with previously reported replacements at the same or topologically equivalent positions
Mutation/equivalent mutations . | FVIII:C, % . | FVIII:Ag, % . | Clinical severity . | Inhibitor? . | Reference . |
---|---|---|---|---|---|
p.Asp167Asn | |||||
p.Asp167Tyr | <1 | 1.6 | Moderate† | No | Liu et al68 |
p.Asp167Glu | 9-15 | 5 | Mild | ? | Boekhorst et al19 |
p.Asp167Gly | ? | ? | Mild‡ | ? | Cutler et al74 |
p.Asp542Tyr | <1 | <1 | Severe | No | Akkarapatumwong et al75 |
p.Asp542Gly | <1 | 5 | Severe | No | Higuchi et al76 ; McGinniss et al77 |
p.Asp542His | <1 | ? | Severe | No | Waseem et al55 ; Bogdanova et al78 |
p.Asp542Ala | <1 | ? | Severe | No | Tagariello et al, unpublished§ |
p.Asp1846Tyr | <1 | ? | Severe | No | Becker et al79 |
p.Asp1846Asn | <1 | ? | Severe | No | Becker et al79 |
p.Asp1846Gly | <1 | ? | Severe | No | Casana et al80 |
p.Asp1846Glu | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn235Ser | |||||
p.Asn235Ile | <1 | ? | Severe | ? | Bicocchi et al81 |
p.Asn235Asp | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn618Ile | |||||
p.Asn618Asp | ? | ? | Severe | ? | Leuer et al53 |
p.Asn618Asp | ? | ? | Moderate | ? | Arruda et al82 |
p.Asn618Ser | 31 | 22 | Mild | ? | Roelse et al45 |
p.Asn618Ser | 30 | ? | Mild | Yes | Vlot et al46 |
p.Asn618Ser | ? | ? | Mild | ? | Boekhorst19 |
p.Ans618Ser | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn1922Asp | <1 | ? | Severe | Yes | Traystman et al47 |
p.Asn1922Asp | ? | ? | Moderate | ? | Higuchi et al76 |
p.Asn1922Ser | ? | ? | Severe | ? | Higuchi et al76 |
p.Asn1922Ser | ? | ? | Moderate | ? | Diamond et al83 |
p.Leu242Pro | |||||
p.Leu625Val | 8-12 | ? | Mild | No | Freson et al49 ; Gallardo et al, unpublished§ |
p.Leu625Ser | <1 | 1 | Severe | No | Guillet et al15 |
p.Leu1929Pro | ? | ? | ? | ? | Cutler et al74 |
p.Gly261Asp | |||||
p.Gly643Ala* | <1 | ? | Severe | No | Gallardo et al, unpublished§ |
p.Gly1948Asp | 7 | 49 | Mild/moderate | No | David et al18 |
p.Gly1948Arg | 12 | ? | Mild | No | Ljung et al, unpublished§ |
p.Gly455Val | |||||
p.Ala78Pro | <1 | ? | Severe | Yes | Sukarova-Stefanovska et al84 |
p.Gly455Glu | 1 | ? | Severe | Yes | Waseem et al55 ; Vinciguerra et al85 |
p.Gly455Arg | <1 | ? | Severe | No | Freson et al49 |
p.Gly494Val: p-Gly494Ser | 4 | 23 | Moderate | Yes | Liu et al68 |
p.Pro550Arg | |||||
p.Ala175Thr | 30 | ? | Mild | No | Guillet et al15 |
p.Pro1854Arg | <1 | ? | Severe | No | Bogdanova et al78 ; Becker et al79 |
p.Pro1854Leu | ? | ? | Mild | ? | Lillicrap et al, unpublished§ |
p.Ala1701Val: p.Ala1701Asp | <1 | 1 | Severe | No | David et al14 |
p.Phe1743Leu | |||||
p.Phe436Cys | 3 | ? | Moderate | No | Cutler et al74 |
p.Phe436Cys | ? | ? | Mild/moderate | ? | Bogdanova86 |
p.Phe1743Leu | 8 | ? | Mild | ? | Ahmed et al56 |
p.Gln2087Pro | |||||
p.Gln2246Arg | 4 | 4 | Moderate | No | Schwaab et al48 |
p.Glu2248Arg | ? | ? | Mild/moderate | ? | Boekhorst et al19 |
p.Gln2246Lys | 10 | 4 | Mild | No | David et al14 |
p.Pro2153Leu | |||||
p.Pro2153Gln | 3 | 6 | Moderate | No | Schwaab et al48 |
p.Pro2153Glu | 2 | <5 | Mild/moderate | ? | Jacquemin et al51 |
p.Pro2153Arg | <1 | <1 | Severe | No | Ivaskevicius et al52 ; Leuer et al53 |
p.Pro2310Leu | <1 | ? | Severe | No | Bogdanova et al78 |
p.Ile2317Phe: p.Ser2160Arg | 5 | ? | Moderate | ? | Ahmed et al56 |
Mutation/equivalent mutations . | FVIII:C, % . | FVIII:Ag, % . | Clinical severity . | Inhibitor? . | Reference . |
---|---|---|---|---|---|
p.Asp167Asn | |||||
p.Asp167Tyr | <1 | 1.6 | Moderate† | No | Liu et al68 |
p.Asp167Glu | 9-15 | 5 | Mild | ? | Boekhorst et al19 |
p.Asp167Gly | ? | ? | Mild‡ | ? | Cutler et al74 |
p.Asp542Tyr | <1 | <1 | Severe | No | Akkarapatumwong et al75 |
p.Asp542Gly | <1 | 5 | Severe | No | Higuchi et al76 ; McGinniss et al77 |
p.Asp542His | <1 | ? | Severe | No | Waseem et al55 ; Bogdanova et al78 |
p.Asp542Ala | <1 | ? | Severe | No | Tagariello et al, unpublished§ |
p.Asp1846Tyr | <1 | ? | Severe | No | Becker et al79 |
p.Asp1846Asn | <1 | ? | Severe | No | Becker et al79 |
p.Asp1846Gly | <1 | ? | Severe | No | Casana et al80 |
p.Asp1846Glu | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn235Ser | |||||
p.Asn235Ile | <1 | ? | Severe | ? | Bicocchi et al81 |
p.Asn235Asp | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn618Ile | |||||
p.Asn618Asp | ? | ? | Severe | ? | Leuer et al53 |
p.Asn618Asp | ? | ? | Moderate | ? | Arruda et al82 |
p.Asn618Ser | 31 | 22 | Mild | ? | Roelse et al45 |
p.Asn618Ser | 30 | ? | Mild | Yes | Vlot et al46 |
p.Asn618Ser | ? | ? | Mild | ? | Boekhorst19 |
p.Ans618Ser | <1 | ? | Severe | No | Ljung et al, unpublished§ |
p.Asn1922Asp | <1 | ? | Severe | Yes | Traystman et al47 |
p.Asn1922Asp | ? | ? | Moderate | ? | Higuchi et al76 |
p.Asn1922Ser | ? | ? | Severe | ? | Higuchi et al76 |
p.Asn1922Ser | ? | ? | Moderate | ? | Diamond et al83 |
p.Leu242Pro | |||||
p.Leu625Val | 8-12 | ? | Mild | No | Freson et al49 ; Gallardo et al, unpublished§ |
p.Leu625Ser | <1 | 1 | Severe | No | Guillet et al15 |
p.Leu1929Pro | ? | ? | ? | ? | Cutler et al74 |
p.Gly261Asp | |||||
p.Gly643Ala* | <1 | ? | Severe | No | Gallardo et al, unpublished§ |
p.Gly1948Asp | 7 | 49 | Mild/moderate | No | David et al18 |
p.Gly1948Arg | 12 | ? | Mild | No | Ljung et al, unpublished§ |
p.Gly455Val | |||||
p.Ala78Pro | <1 | ? | Severe | Yes | Sukarova-Stefanovska et al84 |
p.Gly455Glu | 1 | ? | Severe | Yes | Waseem et al55 ; Vinciguerra et al85 |
p.Gly455Arg | <1 | ? | Severe | No | Freson et al49 |
p.Gly494Val: p-Gly494Ser | 4 | 23 | Moderate | Yes | Liu et al68 |
p.Pro550Arg | |||||
p.Ala175Thr | 30 | ? | Mild | No | Guillet et al15 |
p.Pro1854Arg | <1 | ? | Severe | No | Bogdanova et al78 ; Becker et al79 |
p.Pro1854Leu | ? | ? | Mild | ? | Lillicrap et al, unpublished§ |
p.Ala1701Val: p.Ala1701Asp | <1 | 1 | Severe | No | David et al14 |
p.Phe1743Leu | |||||
p.Phe436Cys | 3 | ? | Moderate | No | Cutler et al74 |
p.Phe436Cys | ? | ? | Mild/moderate | ? | Bogdanova86 |
p.Phe1743Leu | 8 | ? | Mild | ? | Ahmed et al56 |
p.Gln2087Pro | |||||
p.Gln2246Arg | 4 | 4 | Moderate | No | Schwaab et al48 |
p.Glu2248Arg | ? | ? | Mild/moderate | ? | Boekhorst et al19 |
p.Gln2246Lys | 10 | 4 | Mild | No | David et al14 |
p.Pro2153Leu | |||||
p.Pro2153Gln | 3 | 6 | Moderate | No | Schwaab et al48 |
p.Pro2153Glu | 2 | <5 | Mild/moderate | ? | Jacquemin et al51 |
p.Pro2153Arg | <1 | <1 | Severe | No | Ivaskevicius et al52 ; Leuer et al53 |
p.Pro2310Leu | <1 | ? | Severe | No | Bogdanova et al78 |
p.Ile2317Phe: p.Ser2160Arg | 5 | ? | Moderate | ? | Ahmed et al56 |
? indicates not available.
Mutation at the topologically equivalent position in human ceruloplasmin A2 domain, p.Gly631Arg, leads to impaired copper incorporation.45
Reported as ″severe″ in the HAMSTeRS database.
Reported as ″moderate″ in the HAMSTeRS database. Altogether, absence of a fold-stabilizing side chain and cavity formation at this position appear to have less deleterious effects on the domain structure than clashes between side chains other than Asp and neighboring residues, in particular Trp208 (Figure 3A; Table S1).
Unpublished work included in this table has been deposited with the HAMSTeRS database.